Share on StockTwits

IGI Laboratories (NYSE:IG) Director James C. Gale purchased 5,000 shares of IGI Laboratories stock on the open market in a transaction dated Friday, August 22nd. The shares were purchased at an average cost of $5.90 per share, for a total transaction of $29,500.00. Following the completion of the transaction, the director now directly owns 19,624 shares of the company’s stock, valued at approximately $115,782. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at Zacks downgraded shares of IGI Laboratories from a “neutral” rating to an “underperform” rating in a research note on Monday, July 28th. They now have a $5.00 price target on the stock.

Shares of IGI Laboratories (NYSE:IG) traded down 1.89% on Tuesday, hitting $6.22. The stock had a trading volume of 908,655 shares. IGI Laboratories has a 1-year low of $1.80 and a 1-year high of $6.53. The stock’s 50-day moving average is $5.70 and its 200-day moving average is $5.10. The company’s market cap is $326.4 million.

IGI Laboratories (NYSE:IG) last posted its quarterly earnings results on Thursday, July 24th. The company reported ($0.01) earnings per share (EPS) for the quarter. Analysts expect that IGI Laboratories will post $0.01 EPS for the current fiscal year.

IGI Laboratories, Inc (NYSE:IG) develops, manufactures, fills and packs topical semi-solid and liquid products for cosmetic, cosmeceutical and pharmaceutical customers.

Receive News & Ratings for IGI Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGI Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.